Privia Health Group (NASDAQ:PRVA) Stock Price Expected to Rise, Truist Financial Analyst Says

Privia Health Group (NASDAQ:PRVA - Get Free Report) had its target price boosted by stock analysts at Truist Financial from $27.00 to $28.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Truist Financial's target price points to a potential upside of 22.83% from the stock's previous close.

PRVA has been the topic of several other reports. Stephens reissued an "overweight" rating and set a $26.00 target price on shares of Privia Health Group in a report on Thursday, January 2nd. Canaccord Genuity Group increased their target price on Privia Health Group from $29.00 to $30.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Macquarie started coverage on Privia Health Group in a research note on Monday, December 16th. They issued an "outperform" rating and a $25.00 price objective for the company. Piper Sandler raised their target price on Privia Health Group from $25.00 to $40.00 and gave the company an "overweight" rating in a report on Friday, February 28th. Finally, JMP Securities set a $29.00 target price on Privia Health Group in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $26.73.

View Our Latest Stock Report on Privia Health Group

Privia Health Group Trading Down 1.1 %

PRVA stock opened at $22.80 on Thursday. The business's 50 day simple moving average is $23.73 and its 200 day simple moving average is $21.41. Privia Health Group has a 1-year low of $15.92 and a 1-year high of $26.04. The firm has a market capitalization of $2.77 billion, a PE ratio of 227.97, a PEG ratio of 3.47 and a beta of 0.88.

Insider Activity at Privia Health Group

In other news, CFO David Mountcastle sold 5,630 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total value of $125,999.40. Following the completion of the transaction, the chief financial officer now owns 179,676 shares in the company, valued at $4,021,148.88. This trade represents a 3.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 14.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in PRVA. Rhumbline Advisers increased its position in Privia Health Group by 1.3% during the 4th quarter. Rhumbline Advisers now owns 287,200 shares of the company's stock valued at $5,615,000 after buying an additional 3,658 shares in the last quarter. Nordea Investment Management AB increased its stake in Privia Health Group by 33.1% in the 4th quarter. Nordea Investment Management AB now owns 349,773 shares of the company's stock worth $6,953,000 after buying an additional 86,910 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Privia Health Group by 2.2% during the 3rd quarter. Franklin Resources Inc. now owns 1,300,240 shares of the company's stock valued at $23,092,000 after purchasing an additional 28,480 shares during the last quarter. Barclays PLC grew its holdings in Privia Health Group by 240.3% during the 3rd quarter. Barclays PLC now owns 224,018 shares of the company's stock valued at $4,079,000 after buying an additional 158,188 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Privia Health Group by 8.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 188,384 shares of the company's stock valued at $3,430,000 after buying an additional 14,641 shares in the last quarter. Hedge funds and other institutional investors own 94.48% of the company's stock.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.

Further Reading

• Five stocks we like better than Privia Health Group
• How the NYSE and NASDAQ are Different, Why That Matters to Investors
• Broadcom's Big Outperformance Shows Strength Amid Tariff Decline
• Election Stocks: How Elections Affect the Stock Market
• Carvana: Can Turnaround Strength Outdrive Market Headwinds?
• How to trade using analyst ratings
• Meta Seeks Trump's Help in FTC Trial: The Implications Are Huge

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Privia Health Group Right Now?

Before you consider Privia Health Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Privia Health Group wasn't on the list.

While Privia Health Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here